tradingkey.logo

Evolus Inc

EOLS

6.420USD

-0.100-1.53%
Cierre 09/18, 16:00ETCotizaciones retrasadas 15 min
414.98MCap. mercado
PérdidaP/E TTM
Más Datos de Evolus Inc Compañía
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Información de la empresa
Símbolo de cotizaciónEOLS
Nombre de la empresaEvolus Inc
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi
Número de empleados332
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección520 Newport Center Dr Ste 1200
CiudadNEWPORT BEACH
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92660-7022
Teléfono19492844555
Sitio Webhttps://www.evolus.com/
Símbolo de cotizaciónEOLS
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMr. David Moatazedi
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 23 de ago
Actualizado: sáb., 23 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.73%
Nantahala Capital Management, LLC
6.49%
Lynch (Timothy Patrick)
6.33%
BlackRock Institutional Trust Company, N.A.
5.64%
Caligan Partners, LP
5.17%
Otro
68.65%
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.73%
Nantahala Capital Management, LLC
6.49%
Lynch (Timothy Patrick)
6.33%
BlackRock Institutional Trust Company, N.A.
5.64%
Caligan Partners, LP
5.17%
Otro
68.65%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
38.42%
Investment Advisor
26.05%
Investment Advisor/Hedge Fund
15.57%
Individual Investor
8.31%
Private Equity
7.59%
Corporation
3.30%
Research Firm
2.02%
Bank and Trust
0.56%
Pension Fund
0.56%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
362
58.85M
90.98%
-2.31M
2025Q1
367
61.71M
95.75%
-6.80M
2024Q4
349
59.00M
93.18%
-8.33M
2024Q3
345
58.57M
92.95%
-9.62M
2024Q2
337
59.72M
95.46%
-6.66M
2024Q1
324
57.99M
95.42%
-6.59M
2023Q4
309
53.87M
93.36%
-7.99M
2023Q3
309
51.63M
90.65%
-8.83M
2023Q2
309
53.08M
93.27%
-5.08M
2023Q1
308
49.88M
88.43%
-4.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tang Capital Management, LLC
5.00M
7.75%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.65M
5.66%
+521.19K
+16.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.82M
5.93%
-13.22K
-0.34%
Mar 31, 2025
Caligan Partners, LP
2.73M
4.24%
+38.77K
+1.44%
Mar 31, 2025
The Vanguard Group, Inc.
3.22M
5%
+62.66K
+1.98%
Mar 31, 2025
Perceptive Advisors LLC
4.13M
6.4%
-1.02M
-19.76%
Mar 31, 2025
Medy Tox Inc
2.14M
3.31%
-1.24M
-36.82%
Dec 31, 2024
Soleus Capital Management, L.P.
1.08M
1.67%
+382.00K
+54.79%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
0.86%
iShares U.S. Pharmaceuticals ETF
0.19%
iShares Micro-Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Global X Russell 2000 ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Fidelity MSCI Health Care Index ETF
0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción0.86%
iShares U.S. Pharmaceuticals ETF
Proporción0.19%
iShares Micro-Cap ETF
Proporción0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.09%
iShares Russell 2000 Growth ETF
Proporción0.03%
iShares Russell 2000 ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.02%
Schwab U.S. Small-Cap ETF
Proporción0.01%
Fidelity MSCI Health Care Index ETF
Proporción0.01%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI